Skip to main content
SpringerLink
Log in

Diazepam in the Treatment of Moderate to Severe Alcohol Withdrawal

  • Current Opinion
  • Published:
CNS Drugs Aims and scope Submit manuscript

Abstract

Benzodiazepines ameliorate or prevent the symptoms and complications of moderate to severe alcohol withdrawal, which can include autonomic hyperactivity, agitation, combativeness, hallucinations, seizures, delirium, and death. The benzodiazepines most commonly used for this purpose are lorazepam, chlordiazepoxide, oxazepam, and diazepam. It is widely asserted that no member of this group is superior to the others for treatment of alcohol withdrawal. However, of these, diazepam has the shortest time to peak effect, which facilitates both rapid control of symptoms and accurate titration to avoid over-sedation. Furthermore, diazepam and its active metabolite, desmethyldiazepam, have the longest elimination half-lives, so their levels decrease in a gradual, self-tapering manner, resulting in a smoother withdrawal, i.e., a lower incidence and severity of both breakthrough symptoms and rebound phenomena, including a possibly decreased seizure risk. Importantly, the fear of increased risk of over-sedation with diazepam compared with other benzodiazepines is based on a misunderstanding of its pharmacokinetics and is unfounded. Similarly, the notion that diazepam should be avoided in patients with liver disease and elderly patients to avoid prolonged over-sedation is based on no more than conjecture. In fact, there is clinical evidence that diazepam is safe for the treatment of alcohol withdrawal in these patients when administered using a simple symptom-based approach. There is one instance in which diazepam should not be used: when intramuscular administration is the only option, the lipophilicity of diazepam can result in slow absorption—either lorazepam or, when rapid control of symptoms is required, midazolam should be used. The comparative pharmacokinetics of the benzodiazepines used in the treatment of alcohol withdrawal together with a comprehensive review of the literature on their use strongly suggest that diazepam should be the preferred benzodiazepine for the treatment of patients experiencing moderate to severe alcohol withdrawal under most circumstances.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Erdozain AM, Callado LF. Neurobiological alterations in alcohol addiction: a review. Adicciones. 2014;26(4):360–70.

    Article  PubMed  Google Scholar 

  2. Schuckit MA. Recognition and management of withdrawal delirium (Delirium Tremens). N Engl J Med. 2014;371(22):2109–13.

    Article  PubMed  Google Scholar 

  3. Sereny G, Kalant H. Comparative clinical evaluation of chlordiazepoxide and promazine in treatment of alcohol-withdrawal syndrome. Br Med J. 1965;1(5427):92–7.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  4. Kaim SC, Kaim SC, Klett CJ, Klett CJ, Rothfeld B, Rothfeld B. Treatment of the acute alcohol withdrawal state: a comparison of four drugs. Am J Psychiatry. 1969;125(12):1640–6.

    Article  CAS  PubMed  Google Scholar 

  5. Thompson WL, Johnson AD, Maddrey WL. Diazepam and paraldehyde for treatment of severe delirium tremens. A controlled trial. Ann Intern Med. 1975;82(2):175–80.

    Article  CAS  PubMed  Google Scholar 

  6. Amato L, Minozzi S, Davoli M. Efficacy and safety of pharmacological interventions for the treatment of the alcohol withdrawal syndrome. Cochrane Database Syst Rev. 2011;6:CD008537. doi:10.1002/14651858.CD008537.pub2.

  7. Greenblatt DJ, Greenblatt M. Which drug for alcohol withdrawal? J Clin Pharmacol New Drugs. 1972;12(11):429–31.

    Article  CAS  PubMed  Google Scholar 

  8. Sellers EM, Kalant H. Alcohol intoxication and withdrawal. N Engl J Med. 1976;294(14):757–62.

    Article  PubMed  Google Scholar 

  9. Romach MK, Sellers EM. Management of the alcohol withdrawal syndrome. Annu Rev Med. 1991;42:323–40.

    Article  CAS  PubMed  Google Scholar 

  10. Holbrook AM, Crowther R, Lotter A, Cheng C, King D. Meta-analysis of benzodiazepine use in the treatment of acute alcohol withdrawal. Can Med Assoc J. 1999;160(5):649–55.

    CAS  Google Scholar 

  11. Amato L, Minozzi S, Vecchi S, Davoli M. Benzodiazepines for alcohol withdrawal. Cochrane Database Syst Rev. 2010;3:CD005063. doi:10.1002/14651858.CD005063.pub3.

  12. Perry EC. Inpatient management of acute alcohol withdrawal syndrome. CNS Drugs. 2014;28(5):401–10.

    Article  CAS  PubMed  Google Scholar 

  13. Mirijello A, D’Angelo C, Ferrulli A, Vassallo G, Antonelli M, Caputo F, et al. Identification and management of alcohol withdrawal syndrome. Drugs. 2015;75(4):353–65.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  14. Lejoyeux M, Solomon J, Adès J. Benzodiazepine treatment for alcohol-dependent patients. Alcohol Alcohol. 1998;33(6):563–75.

    Article  CAS  PubMed  Google Scholar 

  15. Mayo-Smith MF, Beecher LH, Fischer TL, Gorelick DA, Guillaume JL, Hill A, et al. Management of alcohol withdrawal delirium. An evidence-based practice guideline. Arch Intern Med. 2004;164(13):1405–12.

    Article  CAS  PubMed  Google Scholar 

  16. Mayo-Smith MF. Pharmacological management of alcohol withdrawal. A meta-analysis and evidence-based practice guideline. American Society of Addiction Medicine Working Group on Pharmacological Management of Alcohol Withdrawal. JAMA. 1997;278(2):144–51.

    Article  CAS  PubMed  Google Scholar 

  17. Solomon J, Rouck LA, Koepke HH. Double-blind comparison of lorazepam and chlordiazepoxide in the treatment of the acute alcohol abstinence syndrome. Clin Ther. 1983;6(1):52–8.

    CAS  PubMed  Google Scholar 

  18. ÓBrien JE, Meyer RE, Thoms DC. Double-blind comparison of lorazepam and diazepam in the treatment of the acute alcohol abstinence syndrome. Curr Ther Res Clin Exp. 1983;34(5):825–31.

  19. Miller WC, McCurdy L. A double-blind comparison of the efficacy and safety of lorazepam and diazepam in the treatment of the acute alcohol withdrawal syndrome. Clin Ther. 1984;6(3):364–71.

    PubMed  Google Scholar 

  20. Kumar CN, Andrade C, Murthy P. A randomized, double-blind comparison of lorazepam and chlordiazepoxide in patients with uncomplicated alcohol withdrawal. J Stud Alcohol Drugs. 2009;70(3):467–74.

    Article  PubMed  Google Scholar 

  21. Rajmohan V, Sushil K, Mohandas E. A double blind randomised comparison of chlordiazepoxide and lorazepam in alcohol withdrawal. Asian J Psychiatr. 2013;6(5):401–3.

    Article  CAS  PubMed  Google Scholar 

  22. Ramanujam R, Padma L, Swaminath G, Thimmaiah RS. A comparative study of the clinical efficacy and safety of lorazepam and chlordiazepoxide in alcohol dependence syndrome. J Clin Diagn Res. 2015;9(3):FC10-3.

    PubMed  PubMed Central  Google Scholar 

  23. Muzyk AJ, Leung JG, Nelson S, Embury ER, Jones SR. The role of diazepam loading for the treatment of alcohol withdrawal syndrome in hospitalized patients. Am J Addict. 2013;22(2):113–8.

    Article  PubMed  Google Scholar 

  24. Thompson WL. Management of alcohol withdrawal syndromes. Arch Intern Med. 1978;138(2):278–83.

    Article  CAS  PubMed  Google Scholar 

  25. Stehman CR, Mycyk MB. A rational approach to the treatment of alcohol withdrawal in the ED. Am J Emerg Med. 2013;31(4):734–42. doi:10.1016/j.ajem.2012.12.029.

  26. Hoffman RS, Weinhousec GL. Management of moderate and severe alcohol withdrawal syndromes. Waltham, MA: UpToDate. http://www.uptodate.com/contents/management-of-moderate-and-severe-alcohol-withdrawal-syndromes. Accessed 27 July 2016.

  27. Hollister LE. Benzodiazepines—an overview. Br J Clin Pharmacol. 1981;11:117S–9S.

    PubMed Central  Google Scholar 

  28. Arendt RM, Greenblatt DJ, Liebisch DC, Luu MD, Paul SM. Determinants of benzodiazepine brain uptake: lipophilicity versus binding affinity. Psychopharmacology (Berl). 1987;93(1):72–6.

    Article  CAS  PubMed  Google Scholar 

  29. Greenblatt DJ, Ehrenberg BL, Gunderman J, Scavone JM, Tai NT, Harmatz JS, et al. Kinetic and dynamic study of intravenous lorazepam: comparison with intravenous diazepam. J Pharmacol Exp Ther. 1989;250(1):134–40.

    CAS  PubMed  Google Scholar 

  30. Elliott HW. Metabolism of lorazepam. Br J Anaesth. 1976;48(10):1017–23.

    Article  CAS  PubMed  Google Scholar 

  31. Conner JT, Katz RL, Bellville JW, Graham C, Pagano R, Dorey F. Diazepam and lorazepam for intravenous surgical premedication. J Clin Pharmacol. 1978;18(5–6):285–92.

    Article  CAS  PubMed  Google Scholar 

  32. Dundee JW, McGowan WA, Lilburn JK, McKay AC, Hegarty JE. Comparison of the actions of diazepam and lorazepam. Br J Anaesth. 1979;51(5):439–46.

    Article  CAS  PubMed  Google Scholar 

  33. Brown JH, Moggey DE, Shane FH. Delirium tremens: a comparison of intravenous treatment with diazepam and chlordiazepoxide. Scott Med J. 1972;17(1):9–12.

    Article  CAS  PubMed  Google Scholar 

  34. Heinälä P, Piepponen T, Heikkinen H. Diazepam loading in alcohol withdrawal: clinical pharmacokinetics. Int J Clin Pharmacol Ther Toxicol. 1990;28(5):211–7.

    PubMed  Google Scholar 

  35. Duby JJ, Berry AJ, Ghayyem P, Wilson MD, Cocanour CS. Alcohol withdrawal syndrome in critically ill patients: protocolized versus nonprotocolized management. J Trauma Acute Care Surg. 2014;77(6):938–43.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  36. Gold JA, Rimal B, Nolan A, Nelson LS. A strategy of escalating doses of benzodiazepines and phenobarbital administration reduces the need for mechanical ventilation in delirium tremens. Crit Care Med. 2007;35(3):724–30.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  37. Teboul E, Chouinard G. A guide to benzodiazepine selection. Part I: Pharmacological aspects. Can J Psychiatry. 1990;35(8):700–10.

  38. Griffin CE 3rd, Kaye AM, Bueno FR, Kaye AD. Benzodiazepine pharmacology and central nervous system-mediated effects. Ochsner J. 2013;13(2):214–23.

    PubMed  PubMed Central  Google Scholar 

  39. George KA, Dundee JW. Relative amnesic actions of diazepam, flunitrazepam and lorazepam in man. Br J Clin Pharmacol. 1977;4(1):45–50.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  40. Greenblatt DJ, Divoll M. Diazepam versus lorazepam: relationship of drug distribution to duration of clinical action. Adv Neurol. 1983;34:487–91.

    CAS  PubMed  Google Scholar 

  41. Greenblatt DJ, Friedman HL, Shader RI. Correlating pharmacokinetics and pharmacodynamics of benzodiazepines: problems and assumptions. Psychopharmacol Ser. 1987;3:62–71.

    CAS  PubMed  Google Scholar 

  42. Bird RD, Makela EH. Alcohol withdrawal: what is the benzodiazepine of choice? Ann Pharmacother. 1994;28(1):67–71.

    Article  CAS  PubMed  Google Scholar 

  43. Kendall MJ, Clarke SW. Prolonged coma after tetanus. Br Med J. 1972;1(5796):354–5.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  44. Kales A, Scharf MB, Kales JD, Soldatos CR. Rebound insomnia. A potential hazard following withdrawal of certain benzodiazepines. JAMA. 1979;241(16):1692–5.

    Article  CAS  PubMed  Google Scholar 

  45. Scharf MB, Kales A, Bixler EO, Jacoby JA, Schweitzer PK. Lorazepam-efficacy, side effects, and rebound phenomena. Clin Pharmacol Ther. 1982;31(2):175–9.

    Article  CAS  PubMed  Google Scholar 

  46. Greenblatt DJ, Shader RI, Abernethy DR. Drug therapy. Current status of benzodiazepines. N Engl J Med. 1983;309(6):354–8.

    Article  CAS  PubMed  Google Scholar 

  47. Kales A, Soldatos CR, Bixler EO, Kales JD, Vela-Bueno A. Diazepam: effects on sleep and withdrawal phenomena. J Clin Psychopharmacol. 1988;8(5):340–6.

    Article  CAS  PubMed  Google Scholar 

  48. Hallfors DD, Saxe L. The dependence potential of short half-life benzodiazepines: a meta-analysis. Am J Public Health. 1993;83(9):1300–4.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  49. Hoey LL, Nahum A, Vance-Bryan K. A prospective evaluation of benzodiazepine guidelines in the management of patients hospitalized for alcohol withdrawal. Pharmacotherapy. 1994;14(5):579–85.

    CAS  PubMed  Google Scholar 

  50. Chouinard G. Issues in the clinical use of benzodiazepines: potency, withdrawal, and rebound. J Clin Psychiatry. 2004;65(Suppl 5):7–12.

    CAS  PubMed  Google Scholar 

  51. Ashton H. The diagnosis and management of benzodiazepine dependence. Curr Opin Psychiatry. 2005;18(3):249–55.

    Article  PubMed  Google Scholar 

  52. Ritson B, Chick J. Comparison of two benzodiazepines in the treatment of alcohol withdrawal: effects on symptoms and cognitive recovery. Drug Alcohol Depend. 1986;18(4):329–34.

    Article  CAS  PubMed  Google Scholar 

  53. Hill A, Williams D. Hazards associated with the use of benzodiazepines in alcohol detoxification. J Subst Abuse Treat. 1993;10(5):449–51.

    Article  CAS  PubMed  Google Scholar 

  54. Mayo-Smith MF, Bernard D. Late-onset seizures in alcohol withdrawal. Alcohol Clin Exp Res. 1995;19(3):656–9.

    Article  CAS  PubMed  Google Scholar 

  55. Devenyi P, Harrison ML. Prevention of alcohol withdrawal seizures with oral diazepam loading. Can Med Assoc J. 1985;132(7):798–800.

    CAS  PubMed  PubMed Central  Google Scholar 

  56. Stanski DR, Greenblatt DJ, Selwyn A, Shader RI, Franke K, Koch-Weser J. Plasma and cerebrospinal fluid concentrations of chlordiazepoxide and its metabolites in surgical patients. Clin Pharmacol Ther. 1976;20(5):571–8.

    Article  CAS  PubMed  Google Scholar 

  57. Greenblatt DJ, Shader RI, Franke K, Harmatz JS. Pharmacokinetics of chlordiazepoxide and metabolites following single and multiple oral doses. Int J Clin Pharmacol Biopharm. 1978;16(10):486–93.

    CAS  PubMed  Google Scholar 

  58. Greenblatt DJ, Shader RI, MacLeod SM, Sellers EM. Clinical pharmacokinetics of chlordiazepoxide. Clin Pharmacokinet. 1978;3(5):381–94.

    Article  CAS  PubMed  Google Scholar 

  59. Lin KM, Friedel RO. Relationship of plasma levels of chlordiazepoxide and metabolites to clinical response. Am J Psychiatry. 1979;136(1):18–23.

    Article  CAS  PubMed  Google Scholar 

  60. Minder EI. Toxicity in a case of acute and massive overdose of chlordiazepoxide and its correlation to blood concentration. J Toxicol Clin Toxicol. 1989;27(1–2):117–27.

    Article  CAS  PubMed  Google Scholar 

  61. Sainati SM, Lorens SA. Intra-raphe benzodiazepines enhance rat locomotor activity: interactions with GABA. Pharmacol Biochem Behav. 1983;18(3):407–14.

    Article  CAS  PubMed  Google Scholar 

  62. DrugPatentWatch [database on the Internet]. http://www.drugpatentwatch.com. Accessed 27 July 2016.

  63. Frew B, Frew JR, Swift CF. Competition Between Original Brands and Generics in Pharmaceuticals: Analysis and Policy Implications. In: Bellur VV, editor. The 1980’s: A Decade of Marketing Challenges. Cham: Springer International Publishing; 2015. p. 282–5.

    Google Scholar 

  64. Shader RI, Greenblatt DJ. Benzodiazepines: some aspects of their clinical pharmacology. Ciba Found Symp. 1979;74:141–55.

    Google Scholar 

  65. Sellers EM, Naranjo CA, Harrison M, Devenyi P, Roach C, Sykora K. Diazepam loading: simplified treatment of alcohol withdrawal. Clin Pharmacol Ther. 1983;34(6):822–6.

    Article  CAS  PubMed  Google Scholar 

  66. Manikant S, Tripathi BM, Chavan BS. Loading dose diazepam therapy for alcohol withdrawal state. Indian J Med Res. 1993;98:170–3.

    CAS  PubMed  Google Scholar 

  67. Salloum IM, Cornelius JR, Daley DC, Thase ME. The utility of diazepam loading in the treatment of alcohol withdrawal among psychiatric inpatients. Psychopharmacol Bull. 1995;31(2):305–10.

    CAS  PubMed  Google Scholar 

  68. Wasilewski D, Matsumoto H, Kur E, Dziklinska A, Wozny E, Stencka K, et al. Assessment of diazepam loading dose therapy of delirium tremens. Alcohol Alcohol. 1996;31(3):273–8.

    Article  CAS  PubMed  Google Scholar 

  69. Hyatt M, Cheever T, Eldot R. Diazepam Loading for Alcohol Detoxification. Am J Addict. 1996;5(4):354–8.

    Article  Google Scholar 

  70. Sellers EM. Clinical pharmacology and therapeutics of benzodiazepines. Can Med Assoc J. 1978;118(12):1533–8.

    CAS  PubMed  PubMed Central  Google Scholar 

  71. Schenker S. Effects of liver disease and of aging on the disposition and elimination of sedatives. Trans Am Clin Climatol Assoc. 1978;89:91–9.

    CAS  PubMed  PubMed Central  Google Scholar 

  72. Ochs HR, Greenblatt DJ, Eckardt B, Harmatz JS, Shader RI. Repeated diazepam dosing in cirrhotic patients: cumulation and sedation. Clin Pharmacol Ther. 1983;33(4):471–6.

    Article  CAS  PubMed  Google Scholar 

  73. Naranjo CA, Busto U, Janecek E, Ruiz I, Roach CA, Kaplan K. An intensive drug monitoring study suggesting possible clinical irrelevance of impaired drug disposition in liver disease. Br J Clin Pharmacol. 1983;15(4):451–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  74. Perry PJ, Wilding DC, Fowler RC, Hepler CD, Caputo JF. Absorption of oral intramuscular chlordiazepoxide by alcoholics. Clin Pharmacol Ther. 1978;23(5):535–41.

    Article  CAS  PubMed  Google Scholar 

  75. Greenblatt DJ, Shader RI, Koch-Weser J. Slow absorption of intramuscular chlordiazepoxide. N Engl J Med. 1974;291(21):1116–8.

    Article  CAS  PubMed  Google Scholar 

  76. Divoll M, Greenblatt DJ, Ochs HR, Shader RI. Absolute bioavailability of oral and intramuscular diazepam: effects of age and sex. Anesth Analg. 1983;62(1):1–8.

    Article  CAS  PubMed  Google Scholar 

  77. Greenblatt DJ, Shader RI, Franke K, MacLaughlin DS, Harmatz JS, Allen MD, et al. Pharmacokinetics and bioavailability of intravenous, intramuscular, and oral lorazepam in humans. J Pharm Sci. 1979;68(1):57–63.

    Article  CAS  PubMed  Google Scholar 

  78. Greenblatt DJ, Divoll M, Harmatz JS, Shader RI. Pharmacokinetic comparison of sublingual lorazepam with intravenous, intramuscular, and oral lorazepam. J Pharm Sci. 1982;71(2):248–52.

    Article  CAS  PubMed  Google Scholar 

  79. Galvin GM, Jelinek GA. Midazolam: an effective intravenous agent for seizure control. Arch Emerg Med. 1987;4(3):169–72.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  80. Lineaweaver WC, Anderson K, Hing DN. Massive doses of midazolam infusion for delirium tremens without respiratory depression. Crit Care Med. 1988;16(3):294–5.

    Article  CAS  PubMed  Google Scholar 

  81. Newman JP, Terris DJ, Moore M. Trends in the management of alcohol withdrawal syndrome. Laryngoscope. 1995;105(1):1–7.

    Article  CAS  PubMed  Google Scholar 

  82. Reves JG, Fragen RJ, Vinik HR, Greenblatt DJ. Midazolam: pharmacology and uses. Anesthesiology. 1985;62(3):310–24.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Hospital Medicine, Department of Medicine, Saint Louis Veterans Affairs Medical Center, John Cochran Division, 915 North Grand Avenue, Saint Louis, 63106, MO, USA

    Steven J. Weintraub

  2. Department of Internal Medicine, Washington University School of Medicine, Saint Louis, MO, USA

    Steven J. Weintraub

Authors
  1. Steven J. Weintraub
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Steven J. Weintraub.

Ethics declarations

Funding

None.

Conflict of interest

Steven J. Weintraub has no conflicts of interest.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Weintraub, S.J. Diazepam in the Treatment of Moderate to Severe Alcohol Withdrawal. CNS Drugs 31, 87–95 (2017). https://doi.org/10.1007/s40263-016-0403-y

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40263-016-0403-y

Keywords

Search

Navigation